Together with our data, showing an up-regulation of MMP9 in the blood of MFS patients compared to controls, indicate that MMP9 may represent a potential biomarker and therapeutic target to reduce the growth rate of TAAs in MFS patients. Here, MMP9 is linked to Marfan syndrome.